Citation Impact
Citing Papers
LIM Protein KyoT2 Negatively Regulates Transcription by Association with the RBP-J DNA-Binding Protein
1998 StandoutNobel
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
1995
Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain
1998 StandoutNature
Epstein-Barr virus immortalization: Notch2 interacts with CBF1 and blocks differentiation
1997
Functional Interaction between SEL-10, an F-box Protein, and the Nuclear Form of Activated Notch1 Receptor
2001 StandoutNobel
Structure and Function of Leukocyte Integrins
1990
The Epstein–Barr Virus Latent Membrane Protein 2A PY Motif Recruits WW Domain-Containing Ubiquitin-Protein Ligases
2000
Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1,which simulates an activated CD40 receptor
1998
Expression of Epstein–Barr Virus Transformation–Associated Genes in Tissues of Patients with EBV Lymphoproliferative Disease
1989
The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates
1996 Standout
Roles of the ankyrin repeats and C-terminal region of the mouse Notch1 intracellular region
1998 StandoutNobel
Determinants of Nuclear and Cytoplasmic Ubiquitin-mediated Degradation of MyoD
2003 StandoutNobel
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
2000 StandoutNature
Antagonistic effects ofc-myc and Epstein-Barr virus latent genes on the phenotype of human B cells
2001
The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family
1995
Biology and adoptive cell therapy of Epstein‐Barr virus‐associated lymphoproliferative disorders in recipients of marrow allografts
1997
Global Cancer Statistics, 2002
2005 Standout
Ubiquitin-Proteasome-mediated Degradation of Id1 Is Modulated by MyoD
2004 StandoutNobel
Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade
1997
Epstein–Barr virus in the pathogenesis of NPC
2002
Oncogenic Forms of NOTCH1 Lacking Either the Primary Binding Site for RBP-Jκ or Nuclear Localization Sequences Retain the Ability to Associate with RBP-Jκ and Activate Transcription
1997
Vaccine strategies against Epstein‐Barr virus‐associated diseases: lessons from studies on cytotoxic T‐cell‐mediated immune regulation
1999
Deregulated c‐myc expression in epstein‐barr‐virus‐immortalized b‐cells induces altered growth properties and surface phenotype but not tumorigenicity
1990
Regulation of Interleukin-1β Transcription by Epstein–Barr Virus Involves a Number of Latent Proteins via Their Interaction with RBP
1998 StandoutNobel
Epstein-Barr virus: adaptation to a life within the immune system
1994
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
2007 StandoutNature
Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties
1992 StandoutNobel
Pathogenic roles for Epstein–Barr virus (EBV) gene products in EBV-associated proliferative disorders
2002
Delta-induced Notch Signaling Mediated by RBP-J Inhibits MyoD Expression and Myogenesis
1999 StandoutNobel
The Structural Basis for the Recognition of Diverse Receptor Sequences by TRAF2
1999
Early events in Epstein-Barr virus infection of human B lymphocytes
1991
Cloning and Expression of a Murine Fascin Homolog from Mouse Brain
1995 StandoutNobel
Diagnosis of Nasopharyngeal Carcinoma by DNA Amplification of Tissue Obtained by Fine-Needle Aspiration
1992
Lysine-Independent Ubiquitination of Epstein–Barr Virus LMP2A
2002
Epstein-Barr Virus Provides a New Paradigm: A Requirement for the Immediate Inhibition of Apoptosis
2005
Risk factors in the development of multiple sclerosis
2007
Blinded by the Light: The Growing Complexity of p53
2009 Standout
A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells
2014 StandoutNobel
Epstein–Barr Virus and a Cellular Signaling Pathway in Lymphomas from Immunosuppressed Patients
1998
Lethal effect of the anti-Fas antibody in mice
1993 StandoutNature
The dark side of a tumor suppressor: anti-apoptotic p53
2008
Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death
1991
EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function
2001 StandoutNobel
Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data
1997
LMP1 structure and signal transduction
2001
Functional Interaction between the Mouse Notch1 Intracellular Region and Histone Acetyltransferases PCAF and GCN5
2000 StandoutNobel
Latent membrane protein 1of Epstein-Barr virus interacts with JAK3 and activates STAT proteins
1999
EBV-Infected B Cells in Infectious Mononucleosis
2000
Epstein–Barr virus: 40 years on
2004 Standout
Latent membrane protein 1of Epstein-Barr virus mimics a constitutively active receptor molecule
1997
Head and Neck Cancer
1993 Standout
The Fas Death Factor
1995 StandoutScience
The 5′ flanking region of the gene for the Epstein-Barr virus-encoded nuclear antigen 2 contains a cell type specificcis-acting regulatory element that activates transcription in transfected B-cells
1988
Epstein-Barr Virus Coinfection and Recombination in Non-Human Immunodeficiency Virus-Associated Oral Hairy Leukoplakia
1995
The epstein‐barr‐virus‐encoded membrane protein LMP but not the nuclear antigen EBNA‐1 induces rejection of transfected murine mammary carcinoma cells
1991
Degradation of the Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) by the Ubiquitin-Proteasome Pathway
2000 StandoutNobel
Epstein‐barr virus‐infected b cells persist in the circulation of acyclovir‐treated virus carriers
1989
Epstein–Barr virus and oncogenesis: from latent genes to tumours
2003
Epstein–Barr virus latent membrane protein inhibits human epithelial cell differentiation
1990 Nature
Epstein-barr virus latency: LMP2, a regulator or means for Epstein- barr virus persistence?
2000
Epstein--Barr Virus Gene Expression in Nasopharyngeal Carcinoma
1988
Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
1994 Standout
Structure and function of the WW domain
1996
Co-expression of Epstein-Barr virus latent membrane protein and vimentin in “aggressive” histological subtypes of Hodgkin's disease
1993
Integral membrane protein 2 of Epstein—barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases
1995
The TNF and TNF Receptor Superfamilies
2001 Standout
The Tumor Suppressor Protein p16 and the Human Papillomavirus Oncoprotein-58 E7 Are Naturally Occurring Lysine-less Proteins That Are Degraded by the Ubiquitin System
2004 StandoutNobel
Three transcriptionally distinct forms of epstein-barr virus latency in somatic cell hybrids: Cell phenotype dependence of virus promoter usage
1992
Plasmid cDNA-directed protein synthesis in a coupled eukaryoticin vitrotranscription-translation system
1992 StandoutNobel
RBP-Jkrepression activity is mediated by a co-repressor and antagonized by the Epstein-Barr virus transcription factor EBNA2
1995
The Association of Epstein-Barr Virus (Ebv) with T Cell Lymphoproliferations and hodgkin's Disease: Two New Developments in the Ebv Field
1993
Mediation of Epstein-Barr Virus EBNA2 Transactivation by Recombination Signal-Binding Protein J κ
1994 Science
Both Epstein-Barr Viral Nuclear Antigen 2 (EBNA2) and Activated Notch1 Transactivate Genes by Interacting with the Cellular Protein RBP-Jκ
1997
The Tumor Necrosis Factor Ligand and Receptor Families
1996 StandoutNobel
Epstein–Barr Virus Infection
2000 Standout
Sustained transgene expression in vitro and in vivo using an Epstein–Barr virus replicon vector system combined with HVJ liposomes
1998
Cap-Binding Proteins of Eukaryotic Messenger RNA: Functions in Initiation and Control of Translation
1988
Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein–Barr virus nuclear antigen 1
1997 StandoutNobel
Functional Replacement of the Intracellular Region of the Notch1 Receptor by Epstein-Barr Virus Nuclear Antigen 2
1998 StandoutNobel
The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues
1995
The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B.
1992
Masking of the CBF1/RBPJ κ Transcriptional Repression Domain by Epstein-Barr Virus EBNA2
1995 Science
Epstein–Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter
2000
Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus
1993
The CD8+ Dendritic Cell Subset Selectively Endocytoses Dying Cells in Culture and In Vivo
2002 StandoutNobel
Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes
1992
A Role for SKIP in EBNA2 Activation of CBF1-Repressed Promoters
2000
Epstein-Barr virus nuclear antigen 2 exerts its transactivating function through interaction with recombination signal binding protein RBP-J kappa, the homologue of Drosophila Suppressor of Hairless.
1994 StandoutNobel
Epstein-Barr virus recombinant molecular genetic analysis of the LMP1 amino-terminal cytoplasmic domain reveals a probable structural role, with no component essential for primary B-lymphocyte growth transformation
1994
Epstein-Barr Virus BARF1 Protein Is Dispensable for B-Cell Transformation and Inhibits Alpha Interferon Secretion from Mononuclear Cells
1999
Identification of Virus-Encoded MicroRNAs
2004 StandoutScience
The human J kappa recombination signal sequence binding protein (RBP-J kappa) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements.
1994
Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element
1991
Integrins: Versatility, modulation, and signaling in cell adhesion
1992 Standout
Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro
1992
Epstein-Barr Virus Infections: Biology, Pathogenesis, and Management
1993
Apoptosis in the Pathogenesis and Treatment of Disease
1995 StandoutScience
Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation.
1993
The EBV Transforming Protein, Latent Membrane Protein 1, Mimics and Cooperates with CD40 Signaling in B Lymphocytes
1999
Down-regulation of LFA-1 Adhesion Receptors by C- myc Oncogene in Human B Lymphoblastoid Cells
1990 Science
Signaling Through Scaffold, Anchoring, and Adaptor Proteins
1997 StandoutScience
EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1
1994
Recombination Signal Sequence Binding Protein Jκ Is Constitutively Bound to the NF-κB Site of the Interleukin-6 Promoter and Acts as a Negative Regulatory Factor
1997
Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus [see comments]
1993
An Animal Model for Acute and Persistent Epstein-Barr Virus Infection
1997 Science
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
1992
Antisense to the Epstein-Barr Virus (EBV)-Encoded Latent Membrane Protein 1 (LMP-1) Suppresses LMP-1 and Bcl-2 Expression and Promotes Apoptosis in EBV-Immortalized B Cells
1998
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation
1993
Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice.
1996
Biochemical, genetic, and functional analyses of the phosphorylation sites on the Epstein-Barr virus-encoded oncogenic latent membrane protein LMP-1
1993
How neuroinflammation contributes to neurodegeneration
2016 StandoutScience
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.
1987
Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers
1994
The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein.
1994
Epstein-Barr virus nuclear antigen 3C is a transcriptional regulator
1995
A region of herpes simplex virus VP16 can substitute for a transforming domain of Epstein-Barr virus nuclear protein 2.
1992
Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1
1995
NF-κB inhibition causes spontaneous apoptosis in Epstein–Barr virus-transformed lymphoblastoid cells
2000
Viruses in Human Cancers
1991 StandoutScienceNobel
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.
1993
The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein.
1993
The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa)
1996
Transformation by the oncogenic latent membrane protein correlates with its rapid turnover, membrane localization, and cytoskeletal association
1991
Negative-strand RNA viruses: genetic engineering and applications.
1996
Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype
1992
Truncated Mammalian Notch1 Activates CBF1/RBPJk-Repressed Genes by a Mechanism Resembling That of Epstein-Barr Virus EBNA2
1996
Epstein-Barr virus infection induces expression in B lymphocytes of a novel gene encoding an evolutionarily conserved 55-kilodalton actin-bundling protein
1994
Mimicry of CD40 Signals by Epstein-Barr Virus LMP1 in B Lymphocyte Responses
1999 Science
RBP-L, a Transcription Factor Related to RBP-Jκ
1997 StandoutNobel
Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells.
1996 StandoutNobel
Epstein-Barr virus intrastrain recombination in oral hairy leukoplakia
1994
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Tolerogenic Dendritic Cells
2003 StandoutNobel
Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors
1993
Human Cd4+ T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen Ebna1
2000 StandoutNobel
Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide
2004
The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction
2002 StandoutNobel
Epstein-Barr Virus and the Somatic Hypermutation of Immunoglobulin Genes in Burkitt's Lymphoma Cells
2001
Transient up-regulation of P2Y2nucleotide receptor mRNA expression is an immediate early gene response in activated thymocytes
1997 StandoutNobel
Contribution of conserved amino acids in mediating the interaction between EBNA2 and CBF1/RBPJk
1995
Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia.
1995
Noncytopathic Sindbis virus RNA vectors for heterologous gene expression
1998 StandoutNobel
Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa
1995
A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes
1996
Role of the TRAF Binding Site and NF-κB Activation in Epstein-Barr Virus Latent Membrane Protein 1-Induced Cell Gene Expression
1998
LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha
1995
Identification and characterization of an Epstein-Barr virus nuclear antigen 2-responsive cis element in the bidirectional promoter region of latent membrane protein and terminal protein 2 genes
1994
The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter.
1993
Recombination signal sequence-binding protein Jκ alters mesodermal cell fate decisions by suppressing cardiomyogenesis
2003 StandoutNobel
The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation
1991
A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of Jkappa
1996
Works of F Wang being referenced
Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance
2006
Definitive identification of a member of the Epstein-Barr virus nuclear protein 3 family.
1986
Comparative analysis identifies conserved tumor necrosis factor receptor-associated factor 3 binding sites in the human and simian Epstein-Barr virus oncogene LMP1
1996
Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression
1991
Epstein-Barr virus (EBV) recombinants: use of positive selection markers to rescue mutants in EBV-negative B-lymphoma cells
1991
Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation
1991
5' Coding and regulatory region sequence divergence with conserved function of the Epstein-Barr virus LMP2A homolog in herpesvirus papio
1995
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23
1990
Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity
1988
Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.
1989